TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9835004
Drug: All patients
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients (including both aprotinin doses)
Study: 15805205
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1000 mg administered intravenously five minutes before skin incision)
Study: 23415635
Drug: Intracoronary adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary adenosine 600 μg
Study: 9029744
Drug: 25-cm2 once-a-week
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25-cm2 once-a-week adhesive patch
Study: 25278226
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin therapy during lung resection
Study: 16140428
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg daily for 4 weeks)
Study: 7023207
Drug: Single-dose trimethoprim
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose trimethoprim (200 mg)
Study: 7023207
Drug: Five-day course
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-day course of trimethoprim (200 mg b.d.)
Study: 15163340
Drug: T4 monotherapy
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T4 monotherapy
Study: 26903582
Drug: Intra-arterial treatment
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial treatment (IAT) with retrievable stents
Study: 17548440
Drug: NAb-positive patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAb-positive patients during treatment months 0-6
Study: 28153654
Drug: Intravenous dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dextrose 5% with normal saline
Study: 1909692
Drug: Oral cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine A (5 mg/kg/day) for 12 weeks
Study: 9005368
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate 3.75 mg monthly intramuscularly
Study: 22237311
Drug: SB-649868 10
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-649868 10 mg
Study: 21806767
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg, then titrated to 10 mg
Study: 10325289
Drug: Danazol 600
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 600 mg daily for 3 months
Study: 12419084
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE) 0.625 mg/day and medroxyprogesterone acetate (MPA) 5 mg/day
Study: 8700340
Drug: Acarbose 300
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose 300 mg/day
Study: 17226908
Drug: Discontinuous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Discontinuous ciprofloxacin treatment (200 mg intravenous injection for 30 min before ERCP and discontinued after ERCP)
Study: 26606200
Drug: 74-Gy radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 74-Gy radiation therapy (RT) with concurrent and consolidation carboplatin/paclitaxel
Study: 15232796
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 supplement
Study: 3802729
Drug: Cimetidine hydrochloride
Normalized name: Cimetidine Hydrochloride
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine hydrochloride 300 mg i.v. every six hours, beginning one hour before lidocaine administration
Study: 1339011
Drug: Cisplatinum 40
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatinum 40 mg/m2/day + Etoposide 100 mg/m2/day (arm B)
Study: 2185157
Drug: Ampicillin alone
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin alone or in combination with chloramphenicol
Study: 20185637
Drug: Oral tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral tolvaptan
Study: 18163521
Drug: Subcutaneous methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous methotrexate (15 mg/week for 24 weeks)
Study: 9233903
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) 160 mg/d
Study: 51284
Drug: Inhaled betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled betamethasone valerate
Study: 11731186
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated estrogens (0.625 mg)/micronised progesterone (200 mg)
Study: 26314821
Drug: Urticaria Patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urticaria Patient Daily Diary (UPDD)
Study: 24612081
Drug: Low-onion group
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-onion group (raw red onions: 2 × 10-15 g/day)
Study: 24892114
Drug: 2-stage procedure
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-stage procedure with implant placement delayed by 4 months
Study: 30497530
Drug: neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant chemotherapy with bevacizumab
Study: 23632404
Drug: Oral acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acetazolamide (ACZ)
Study: 29608680
Drug: Bolus infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus infusion (30 minutes) of beta-lactams
Study: 1965288
Drug: Fluoride dentifrices
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride dentifrices containing anticalculus agents (soluble pyrophosphates, zinc chloride, zinc oxide)
Study: 26025798
Drug: Rest without
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rest without treatment (Control)
Study: 1898841
Drug: Clonidine plus
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine plus Morphine
Study: 25193390
Drug: Transenteral (TE)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transenteral (TE) bowel preparation
Study: 15801919
Drug: Prolonged lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prolonged lamivudine treatment
Study: 9210677
Drug: Cefdinir 600
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir 600 mg once a day for 10 days
Study: 26994623
Drug: Oxymetazoline (0.05%)
Normalized name: Oxymethazoline
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxymetazoline (0.05%) plus intranasal steroid (budesonide 100 μg/spray)
Study: 18520604
Drug: Low-dose MDMA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose MDMA (1.0 mg/kg)
Study: 29167192
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin peglispro (BIL)
Study: 16846498
Drug: Red palm
Normalized name: Palm Oil
DrugBank: Palm oil (DB14377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red palm oil (RPO) added to school meals (15 ml, 3 times a week)
Study: 16846498
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A capsule (60 mg) given at the end of the school year
Study: 9239586
Drug: Anesthesiologist-administered midazolam-fentanyl
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Anesthesiologist-administered midazolam-fentanyl sedation
Study: 12953327
Drug: Transdermal contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal contraceptive patches delivering ethinyl E2 and norelgestromin
Study: 12444514
Drug: Intraarticular 20
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular 20 mg of tenoxicam and 50 mg bupivacaine (0.25%) in 20 ml normal saline (Group BT)
Study: 14962728
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives for over 3 years
Study: 31225673
Drug: High-dose active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose active treatment
Study: 7048920
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (200 mg five times a day for five days)
Study: 18569991
Drug: Percutaneous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous ethanol injection (PEI)
Study: 15963077
Drug: Rifaximin 1200
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 1200 mg/day
Study: 24169081
Drug: Tadalafil 5mg
Normalized name: TADALAFIL 5MG TAB
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil 5mg once daily
Study: 23582628
Drug: Zofenopril 15
Normalized name: Zofenopril
DrugBank: Zofenopril (DB13166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril 15 to 30 mg/day
Study: 12064344
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) incorporated into meat patties with a daily intake of 18.6 mg catechins/d
Study: 11834236
Drug: Nestorone subdermal
Normalized name: Nestorone
DrugBank: Segesterone acetate (DB14583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nestorone subdermal implant (NES)
Study: 27401980
Drug: dual users
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dual users (substituted half of daily cigarette consumption with e-cigarettes)
Study: 1527539
Drug: Phenytoin BP
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin BP tablets (Regent Laboratories)
Study: 26040200
Drug: Double antibiotic
Normalized name: Double Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double antibiotic paste (DAP) 1 mg ml(‐1)
Study: 29428121
Drug: Traditional intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional intervention (psychiatry and medicine only)
Study: 365670
Drug: Simethicone solution
Normalized name: Simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone solution before peroral endoscopy
Study: 22595362
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 2000 mg/day
Study: 22595362
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) 200 mg/day
Study: 28189575
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (duloxetine or fluoxetine)
Study: 26114240
Drug: Aripiprazole lauroxil
Normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aripiprazole lauroxil 882 mg
Study: 25801872
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (target SBP <140 mm Hg)
Study: 23446088
Drug: NGX-4010 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NGX-4010 treatment
Study: 23289548
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid supplementation (1,470 mg docosahexaenoic acid and 147 mg eicosapentaenoic acid daily)
Study: 6428372
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (mean dose, 1,166 mg/day)
Study: 30887607
Drug: Zoledronate 5
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronate 5 mg
Study: 29530340
Drug: Topical SR-T100
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical SR-T100 gel
Study: 17263737
Drug: Intranasal clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal clonidine 4 microg/kg
Study: 9660042
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine 4 microg/kg
Study: 1728876
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine
Study: 16863518
Drug: Systemic Glucantime
Normalized name: Glucantim
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic Glucantime (20 mg pentavalent antimony/kg/day) plus pentoxifylline (400 mg three times daily) for 20 days
Study: 8033141
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with M‐CSF and gamma‐IFN
Study: 24191305
Drug: Both dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dual therapy and monotherapy
Study: 26607361
Drug: Intravenous regadenoson
Normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous regadenoson 400 μg (2 doses)
Study: 28841916
Drug: Surgery first
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery first (control group) followed by adjuvant chemotherapy (six cycles gemcitabine and capecitabine)
Study: 28841916
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (four cycles FOLFIRINOX) followed by resection
Study: 11812877
Drug: Ferric citrate
Normalized name: Ferric Citrate
DrugBank: Ferric sodium citrate (DB13771)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric citrate (3 g/day)
Study: 25043337
Drug: RBP-7000 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBP-7000 at 60 mg
Study: 25043337
Drug: RBP-7000 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBP-7000 at 90 mg
Study: 21729308
Drug: Intravenous near-isotonic
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous near-isotonic solution (0.81% sodium chloride in glucose)
Study: 8370085
Drug: Nonfloating (NF)
Normalized name: NFS-02
DrugBank: NFS-02 (DB18422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonfloating (NF) hydrophilic matrix capsules
Study: 12966478
Drug: Parecoxib sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib sodium 50 mg
Study: 31060106
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of Daily Living (ADL) III (disabled in some basic ADL)
Study: 20502641
Drug: Oral polio
Normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral polio vaccine (OPV) with BCG
Study: 23496375
Drug: Itraconazole 400
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole 400 mg daily for 6 months plus supportive therapy
Study: 1773908
Drug: Chlorpheniramine maleate
Normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine maleate 12 mg
Study: 31178152
Drug: 12-month trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 12-month trastuzumab treatment
Study: 31178152
Drug: 6-month trastuzumab
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month trastuzumab treatment
Study: 15817604
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m² + carboplatin AUC 5 (arm B)
Study: 22806399
Drug: Apremilast 40
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apremilast 40 mg once per day
Study: 25171902
Drug: Enzalutamide 160
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160 mg/d
Study: 10829042
Drug: Subcutaneous amifostine
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous amifostine 500 mg before each radiotherapy fraction
Study: 17095328
Drug: Tdap vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap vaccine
Study: 23660289
Drug: Intra-arterial abciximab
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial abciximab infusion
Study: 16804032
Drug: Radiofrequency exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency exposure (1,800 MHz, Specific Absorption Rate 2 W/kg) with mitogenic stimulation
Study: 7785755
Drug: Propofol anesthesia
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol anesthesia (1.0-2.5 mg/kg for induction, 4-12 mg/kg for maintenance)
Study: 20799264
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol 200 mg every other week plus methotrexate
Study: 24318743
Drug: Oral phenoxodiol
Normalized name: Phenoxodiol
DrugBank: Idronoxil (DB04915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral phenoxodiol (PXD) plus AUC2-carboplatin
Study: 7527112
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (total dose 20 mg/kg body weight)
Study: 29439147
Drug: IONIS-PTP-1BRx 200
Normalized name: IONIS SOD1Rx
DrugBank: Tofersen (DB14782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IONIS-PTP-1BRx 200 mg once weekly for 26 weeks
Study: 26385134
Drug: Cold gel
Normalized name: Deep Freeze Cold Gel
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold gel pack (3-5 °C)
Study: 25426896
Drug: Ozonated oil
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozonated oil (2 mL daily for 1 week)
Study: 8437319
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral nutrition (EPN)
Study: 23700938
Drug: Standard PD
Normalized name: PD-0299685
DrugBank: PD-0299685 (DB15264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PD solutions (CAPDP-1)
Study: 8404101
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of a polyvalent bacterial extract (BE).
Study: 22952213
Drug: Darexaban 15
Normalized name: Darexaban
DrugBank: Darexaban (DB12289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darexaban 15 mg bid
Study: 26342502
Drug: Oral ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ivermectin 200 μg/kg body weight
Study: 23263729
Drug: Carbon-ion therapy
Normalized name: carbonate ion
DrugBank: Carbonate ion (DB14531)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbon-ion therapy with compensating boli designed for PTV1 and PTV2 at peak-exhalation phase
Study: 3181102
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 30 mg
Study: 10480041
Drug: Guided self-hypnotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-hypnotic relaxation using a standardized protocol and script
Study: 24472402
Drug: SB-705498 12
Normalized name: SB-705498
DrugBank: SB-705498 (DB11883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-705498 12 mg
Study: 9554801
Drug: Cilostazol 200
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 200 mg orally daily for 2 weeks
Study: 7918290
Drug: Oral albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral albendazole 15 mg/kg once daily for 1 month